Crinetics Pharmaceuticals, Inc.
Here’s whether Crinetics Pharmaceuticals, Inc. (CRNX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+17.99% over 10 days); strong 1-year return of +185.3%; 3-month momentum positive (+130.3%). Concerns: RSI 74 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.32x 30d avg). Currently 0.0% off its 52-week high. Score: +4/7.
CRNX is in a confirmed uptrend, trading above both its 50-day ($63.78) and 200-day ($48.12) moving averages. With an RSI of 74.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +185.3% compares to +20.4% for SPY (beat the market by 164.9%).